Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes

Next Previous
X
Search
Trial Profile

Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN-2
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 26 Jun 2023 Results assessing proportion of participants treated with once-weekly semaglutide, or a comparator, achieving a metabolic composite target endpoint from SUSTAIN trials (1 - 5 and 7 - 10) and SUSTAIN China presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 29 Jun 2021 Results of post-hoc analysis of SUSTAIN1-5 & 7-10 presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 29 Jun 2021 Results (n=5680) of post-hoc analysis of data from SUSTAIN 2-4, 7,8,10 studies presented at the 81st Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top